Your account is not claimed yet. You can sign up with ORCID to claim your account.

Erik S Knudsen

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 11

Top Venues

Oncogene

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer research

British journal of cancer

Roswell Park Cancer Institute

University of California (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Roswell Park Cancer Institute Apr 1o 2018

United States

Chairperson, Assistant Director :: Molecular and Cellular Biology/Center for Personalized Medicine

Education History

University of California Aug 15o 1990 - Jun 1o 1996

United States

PHD :: Biology

Publications

Agnieszka K Witkiewicz, Emily Schultz, Jianxin Wang, Deanna Hamilton, Ellis Levine, Tracey O'Connor, Erik S Knudsen
Determinants of response to CDK4/6 inhibitors in the real-world setting. NPJ precision oncology 7 (1) (2023)
Vishnu Kumarasamy, Zhe Gao, Bosheng Zhao, Baishan Jiang, Seth M Rubin, Kevin Burgess, Agnieszka K Witkiewicz, Erik S Knudsen
PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies. British journal of cancer (2023)
Ellen Langille, Khalid N Al-Zahrani, Zhibo Ma, Minggao Liang, Liis Uusküla-Reimand, Roderic Espin Garcia, Katie Teng, Ahmad A Malik, Helga Bergholtz, Samah El Ghamrasni, Somaieh Afiuni-Zadeh, Ricky Tsai, Sana Alvi, Andrew J Elia, YiQing Lü, Robin Hyunseo Oh, Katelyn J Kozma, Daniel Trcka, Masahiro Narimatsu, Jeff C Liu, Thomas Nguyen, Seda Avcioglu Barutcu, Sampath Kumar Loganathan, Rod Bremner, Gary D Baider, Sean E Egan, David W Cescon, Therese Sørlie, Jeffrey L Wrana, Hartland Warren Jackson, Michael D Wilson, Agnieszka K Witkiewicz, Erik S Knudsen, Miguel Angel Pujana, Geoffrey M Wahl, Daniel Schramek
Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer. Cancer discovery 12 (12) (2022)
Vishnu Kumarasamy, Ram Nambiar, Jianxin Wang, Hanna Rosenheck, Agnieszka K Witkiewicz, Erik S Knudsen
RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. Oncogene 41 (27) (2022)
Samera H Hamad, Stephanie A Montgomery, Jeremy M Simon, Brittany M Bowman, Kyle B Spainhower, Ryan M Murphy, Erik S Knudsen, Suzanne E Fenton, Scott H Randell, Jeremiah R Holt, D Neil Hayes, Agnieszka K Witkiewicz, Trudy G Oliver, M Ben Major, Bernard E Weissman
TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene 41 (25) (2022)
Erik S Knudsen, Emily Schultz, Deanna Hamilton, Kris Attwood, Stephen Edge, Tracey O'Connor, Ellis Levine, Agnieszka K Witkiewicz
Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center. The oncologist 27 (8) (2022)
Christos Fountzilas, David L Bajor, Sarbajit Mukherjee, Joel Saltzman, Agnieszka K Witkiewicz, Orla Maguire, Hans Minderman, Ram Nambiar, Hanna R Rosenheck, Erik S Knudsen, Jason B Muhitch, Scott I Abrams, Chong Wang, Alan D Hutson, Kristopher Attwood, Karen A Hicks, Jennifer A Jurcevic, Pawel Kalinski, Renuka Iyer, Patrick M Boland
Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Patrick J Roberts, Vishnu Kumarasamy, Agnieszka K Witkiewicz, Erik S Knudsen
Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows. Molecular cancer therapeutics 19 (8) (2020)
Vishnu Kumarasamy, Paris Vail, Ram Nambiar, Agnieszka K Witkiewicz, Erik S Knudsen
Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition. Cancer research 81 (5) (2020)
Erik S Knudsen, Vishnu Kumarasamy, Sejin Chung, Amanda Ruiz, Paris Vail, Stephanie Tzetzo, Jin Wu, Ram Nambiar, Jared Sivinski, Shailender S Chauhan, Mukund Seshadri, Scott I Abrams, Jianmin Wang, Agnieszka K Witkiewicz
Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut 70 (1) (2020)
Shipra Gandhi, Manu R Pandey, Kristopher Attwood, Wenyan Ji, Agnieszka K Witkiewicz, Erik S Knudsen, Cheryl Allen, Joseph D Tario, Paul K Wallace, Carlos D Cedeno, Maria Levis, Suzanne Stack, Pauline Funchain, Joseph J Drabick, Mark J Bucsek, Igor Puzanov, Hemn Mohammadpour, Elizabeth A Repasky, Marc S Ernstoff
Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (1) (2020)

Erik S Knudsen.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Erik S Knudsen